CD274 and neoplasm: For PD-L1 antibodies, tumor-penetrating peptides (TPPs, e.g., iRGD) enhance tumor accumulation by disrupting the stroma but do not alter the antibody’s binding affinity, leaving the antibody still able to bind normal tissues (e.g., lung epithelium) and trigger irAEs (e.g., pneumonitis) [10,11].